Clinical features of cytopenia with bone marrow hypoplasia in children: an analysis of 100 cases

YANG Wen-Yu; CHEN Xiao-Juan; ZHANG Pei-Hong; Asahito Hama; Masafumi Ito; Seiji Kojima; ZHU Xiao-Fan

doi:10.7499/j.issn.1008-8830.2013.06.013

PDF(1036 KB)

Chinese Journal of Contemporary Pediatrics ›› 2013, Vol. 15 ›› Issue (6) : 448-452. DOI: 10.7499/j.issn.1008-8830.2013.06.013

CLINICAL RESEARCH

Clinical features of cytopenia with bone marrow hypoplasia in children: an analysis of 100 cases

YANG Wen-Yu, CHEN Xiao-Juan, ZHANG Pei-Hong, Asahito Hama, Masafumi Ito, Seiji Kojima, ZHU Xiao-Fan

Author information +

History +

Abstract

OBJECTIVE: To summarize the clinical features of cytopenia with bone marrow hypoplasia in 100 children and to investigate an effective treatment regimen for myelodysplastic syndrome (MDS) in children. METHODS: A retrospective analysis was performed on the clinical data of 100 children non-randomly selected from Japan and China who were diagnosed with cytopenia with bone marrow hypoplasia between 2006 and 2011. The data of patients from China were subjected to prognostic analysis. RESULTS: There was no significant difference in the proportion of MDS cases and acquired aplastic anemia (AA) cases between the Japanese and Chinese children. Of the 100 patients, there were 29 cases of acquired AA, 58 cases of refractory cytopenia of childhood (RCC) and 13 cases of refractory cytopenia with multilineage dysplasia (RCMD). There were significant differences in reticulocyte absolute value in peripheral blood and degree of bone marrow proliferation among the three patient groups (P<0.05). The patients from China were followed up for 16-70 months (median, 41 months). After being treated with cyclosporine (CsA) combined with stanozolol, the patients with AA had response rates of 25% and 75%, the patients with RCC had response rates of 47.1% and 82.4%, and the patients with RCMD had response rates of 60% and 60% respectively at 3 and 6 months after treatment. CONCLUSIONS: There are significant differences in reticulocyte absolute value in peripheral blood and degree of bone marrow proliferation among patients with RCC, RCMD and acquired AA. CsA combined with stanozolol has a good therapeutic efficacy in the treatment of acquired AA and hypoplastic MDS in children, but studies of more cases and a longer follow-up duration are needed.

Key words

Myelodysplastic syndrome / Acquired aplastic anemia / Clinical feature / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

YANG Wen-Yu, CHEN Xiao-Juan, ZHANG Pei-Hong, Asahito Hama, Masafumi Ito, Seiji Kojima, ZHU Xiao-Fan. Clinical features of cytopenia with bone marrow hypoplasia in children: an analysis of 100 cases[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(6): 448-452 https://doi.org/10.7499/j.issn.1008-8830.2013.06.013

References

［1］McCahon E, Tang K, Rogers PC, McBride ML, Schultz KR. The impact of asian descent on the incidence of acquired severe aplastic anaemia in children［J］. British J Haematol, 2003, 121(1): 170-172.

［2］Baumann I, Niemeyer CM, Bennett JM, Shannon K. WHO classification of tumors of-haematopoietic and lymphoid tissues. Childhood myelodysplastic syndrome［M］. 2008: 104-107.

［3］Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach［J］. Haematologica, 2009, 94(2): 264-268.

［4］Rajnoldi AC, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I; European Working Group on Myelodysplastic Syndromes in Childhood(EWOG-MDS). Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS)［J］. Ann Hematol, 2005, 84(7): 429-433.

［5］王颖超，殷楚云，冯磊，王春美，马丽娜，魏永纬，等．免疫抑制疗法治疗儿童再生障碍性贫血疗效分析［J］. 中国当代儿科杂志，2012，14（1）：33-37.

［6］Luna-Fineman S, Shannon KM, Atwater SK, Davis J, Masterson M, Ortega J, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients［J］. Blood, 1999, 93(2):459-466.

［7］Gohring G, Michalova K, Beverloo HB, Betts D, Harbott J, Haas OA, et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome［J］. Blood, 2010, 116(19): 3766-3769.

［8］Passweg JR, Marsh JC. Aplastic anemia: first line treatment by immunosuppression and sibling marrow transplantation［J］. Hematology Am Soc Hematol Educ Program, 2010, 2010(1): 36-42.

［9］Niemeyer CM, Baumann I. Myelodysplastic syndrome in children and adolescents［J］. Semin Hematol, 2008, 45(1): 60-70.

［10］Yoshimi A, Baumann I, Fuhrer M, Bergstr-sser E, G-bel U, Sykora KW, et al. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A inselected children with hypoplastic refractory cytopenia［J］. Haematologica, 2007, 92(3): 397-400.

［11］Yoshimi A, van den Heuvel-Eibrink MM, Baumann I. Immunosuppressive therapy with anti-thymocyte globin and cyclosporine A in patients with refractory cytopenia in childhood［J］. Bone Marrow Transplant, 2011, 46: S369.